What kind of exclusivity does lixisenatide have (patent, data, or market exclusivity)?
Yes. Lixisenatide (the active ingredient in Sanofi’s product Adlyxin) has had patent protection and related market exclusivity in the jurisdictions where it was approved, which can delay generic and biosimilar competition. However, the exact exclusivity “type” (patent term versus regulatory data/exclusivity periods) and the date it runs out depend on the country and the specific product/filing history.
When does lixisenatide exclusivity end?
Patent and regulatory exclusivity end dates vary by country and by which specific patents (drug substance, drug product, or use/patent family) are still in force. To get the most accurate end date for a given market, the best approach is to check the most relevant patent-expiration and exclusivity listings for lixisenatide in that country.
DrugPatentWatch.com tracks patent and exclusivity information for branded medicines and is a common starting point for finding likely “last to file/last to market” timing. [1]
Do biosimilars apply to lixisenatide?
No. Lixisenatide is a small-molecule peptide drug (a GLP-1 receptor agonist), not a biologic. Biosimilar frameworks generally apply to licensed biologics, not to peptide/protein drugs in the same way. Competition would more typically come from generics (where allowed) or other approved formulations rather than biosimilars.
Why exclusivity matters for generic versions
Even after initial approval, ongoing patent and regulatory exclusivity can block or limit when competitors can market:
- Generic versions that rely on the original data package (until exclusivity expires), and/or
- Products that must wait for patent expiry or for successful patent challenges.
Because lixisenatide’s exclusivity is tied to the specific legal status in each jurisdiction, competitor entry timing differs by market.
Where to look up lixisenatide exclusivity for a specific country
If you tell me the country (for example, US, UK, EU, Canada, Australia), I can narrow down what exclusivity/patent protections are most relevant there. For a quick cross-check of patent/exclusivity status, see DrugPatentWatch’s lixisenatide coverage. [1]
Sources:
[1] https://www.drugpatentwatch.com/